Now showing items 1-6 of 6
Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes
(Springer-Verlag, 2005-11)
Prostate cancer remains a significant health concern for men in the USA as it is a leading cancer diagnosis and a cause of death. With the use of prostate-specific antigen or screening, a stage migration has occurred with ...
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)
(Kluwer Academic Publishers; Springer Science+Business Media, 2005-01)
JM-216 is an orally bioavailable platinum compound with activity against many tumor models. The objective of this study was to determine the safety profile and anti-tumor activity of JM-216 in patients with hormone refractory ...
PAR1-mediated NFΚB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism
(Wiley Subscription Services, Inc., A Wiley Company, 2005-10-15)
We have previously reported that protease-activated receptor 1 (PAR1 or thrombin receptor) is over-expressed in metastatic prostate cancer cell lines compared to prostate epithelial cells. In this study, we examined 1,074 ...
A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions
(Wiley Subscription Services, Inc., A Wiley Company, 2005-10-15)
The pliability of cancer cells to mutate into several different phenotypes in an attempt to find one that will survive and colonize at the metastatic site is a tremendous “hurdle” to overcome in designing novel cancer ...
Phase II trial of fenretinide in advanced renal carcinoma
(Kluwer Academic Publishers; Springer Science + Business Media, Inc., 2005-01)
Purpose : Fenretinide, a synthetic form of retinoid, induced apoptosis even in chemotherapy resistant cell lines. A phase II study was hence conducted to evaluate toxicity and efficacy of fenretinide in metastatic renal ...
The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein
(Wiley Subscription Services, Inc., A Wiley Company, 2005-02-01)
Raf kinase inhibitor protein (RKIP) was originally identified as a protein that bound membrane phospholipids and was named phosphatidylethanolamine binding protein-2 (PEBP-2). RKIP was than identified as a protein that ...